首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1439636

癌症诊断 - 全球市场考量、竞争格局、市场预测 (2030)

Cancer Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按订单生产 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

简介目录图表

全球癌症诊断市场规模到2023年将达到1,251.3亿美元，到2030年将达到2,148.8亿美元，预计2024-2030年期间复合年增长率为9.43%。对癌症诊断产品和服务的需求增加主要是由于世界各地报告的癌症患者数量迅速增加。此外，专注于开发先进癌症诊断产品的製造商数量、各种癌症诊断实验室的建立以及政府加强提高患者对早期癌症检测和管理的认识预计将在未来几年增加。年内推动全球癌症诊断市场。

癌症诊断市场动态

由于全球癌症患者数量的快速增加，癌症诊断市场目前正在蓬勃发展。根据 GLOBOCAN 2020 年发布的数据，全球报告了约 19,292,789 例新癌症病例。此外，根据世界卫生组织 (WHO) 2022 年的数据，预计 2020 年全球将有 1,000 万人死于癌症。因此，正确的癌症管理需要早期检测癌症，这导致对癌症诊断的需求不断增加并推动市场。

此外，根据上述数据，吸烟、饮酒、不健康饮食、缺乏运动、致癌感染、空气污染等都是癌症的危险因子。例如，根据世界卫生组织(2022) 的数据，2018 年诊断的癌症中约13% 是由幽门螺旋桿菌、人类乳突病毒(HPV)、乙型肝炎病毒、丙型肝炎病毒和Epstein-Barr 病毒等致癌病毒引起的。

此外，各种癌症诊断产品开发中的技术创新也可能在未来几年为市场做出贡献。将人工智慧技术融入癌症护理中，以提高癌症检测的准确性、速度和效率，也有望推动癌症诊断市场的发展。例如，2022 年 11 月，FDA 批准了 Lunit AI 解决方案用于检测乳癌的 510(k) 许可。

因此，所有上述因素预计将在预测期内加强癌症诊断市场。

然而，与癌症影像诊断设备相关的副作用以及癌症诊断产品的高成本可能会阻碍全球癌症诊断市场的发展。

此外，前所未有的 COVID-19 大流行对癌症诊断市场产生了负面影响。这是因为世界上大多数国家都实施了严格的限制措施来遏制传播。此外，随着重点转向维持卫生系统能力和保护高风险患者免受病毒感染，癌症患者在获得治疗方面面临越来越多的挑战。例如，根据美国国家癌症研究所提供的数据（2022 年），除了因COVID-19 大流行而导致的封锁限制相关的挑战之外，仅在2020 年3 月，就有超过800 例肺癌筛检预约因COVID-19 而被推迟。

癌症诊断细分市场分析

癌症诊断产品类型在产品类型领域，试剂/试剂盒类型占了 66% 的巨大市场占有率，预计这一趋势在预测期内将持续下去。这是因为用于检测癌细胞中的细胞讯号传导、细胞增殖和活力、抑癌基因、生物活性蛋白等的试剂和试剂盒已广泛使用。

此外，有助于早期检测和适当管理各种类型癌症的新试剂和试剂盒的监管批准也有望促进该领域的市场成长。

例如，拥有创新的下一代定序 (NGS) 解决方案的体外诊断 (IVD) 公司 Pillar Biosciences 于 2022 年 8 月 5 日宣布，我们已获得 oncoReveal(TM) Dx 的上市前批准 (PMA)肺癌和结肠癌检测，一种基于NGS 组织的伴随诊断测试，可定性检测肿瘤来源DNA 中的体细胞突变。

本报告研究和分析了全球癌症诊断市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

推动癌症诊断市场的因素
- 全球癌症发生率不断上升
- 产品开发中的技术创新
- 扩大癌症诊断製造商的策略性业务活动
- 增加癌症诊断产品的推出
癌症诊断市场的限制与挑战
- 与癌症影像诊断设备相关的副作用
- 癌症诊断产品成本高，部分产品效力有限
癌症诊断市场机遇
- 提高癌症诊断意识
- 发展中国家的医疗保健支出不断增加

第5章癌症诊断的波特五力分析

第6章COVID-19对癌症诊断市场的影响分析

第7章癌症诊断市场布局

依类型
- 产品类型
- 服务
依方法
- 分子诊断
- 影像诊断
- 内视镜检查
- 切片
依癌症类型
- 乳癌
- 大肠癌
- 肺癌
- 摄护腺癌
- 其他
按最终用户
- 医院
- 诊断实验室
- 影像诊断中心
按地区
- 北美
- 欧洲
- 亚太地区
- 其他领域

第 8 章癌症诊断：全球公司占有率分析 - 3 至 5 家主要公司

第9章癌症诊断公司及产品简介

Pillar Biosciences, Inc.
Hologic Inc.
CD Genomics
Natera, Inc.
Agendia Inc.
Biodesix Inc.
INOVIQ Ltd.
HTG Molecular Diagnostics Inc.
Bio-Rad Laboratories, Inc.
Koninklijke Philips N.V.
FUJIFILM Holdings Corporation
Abbott
General Electric Company
Thermo Fisher Scientific Inc.
NeoGenomics Laboratories
F. Hoffmann-La Roche Ltd
Agilent Technologies Inc
Guardant Health
Illumina, Inc.
QIAGEN

第10章KOL观看次数

第 11 章专案方法

第 12 章关于 DelveInsight

第 13 章免责声明与联络我们

简介目录图表

Product Code: DIMDCL0473

Cancer Diagnostic Market By Type (Product Type [Reagent & Kits And Instruments], And Services), By Technique (Molecular Diagnostic [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry], Diagnostic Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans], Endoscopy, Biopsy [Standard Biopsy And Liquid Biopsy]), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Others), by geography, is expected to grow at a significant CAGR forecast till 2030 owing to the growing burden cancer across the globe and rise in various product launches for efficient detection of cancer

The global cancer diagnostic market was valued at USD 125.13 billion in 2023, growing at a CAGR of 9.43% during the forecast period from 2024 to 2030, to reach USD 214.88 billion by 2030. The increase in demand for cancer diagnostic products and services is predominantly attributed to the spike in the cancer cases reported worldwide. In addition, growing manufacturers focus to develop advanced cancer diagnostic products, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among the patients, and others are anticipated to drive the global cancer diagnostic market during the forthcoming years.

Cancer Diagnostic Market Dynamics:

The market for cancer diagnostics is gaining momentum at present due to the surge in cancer cases across the globe. According to the data published by the GLOBOCAN in the year 2020, approximately 19,292,789 new cases of cancer were reported worldwide. Furthermore, as per the World Health Organization (WHO) 2022 data, cancer accounted for an estimated 10 million deaths across the globe in the year 2020. Thus, for proper cancer management, early detection of cancer is necessary which would lead to an increased demand for cancer diagnosis thereby propelling the market.

Additionally, as per the above-mentioned data, tobacco use, alcohol use, unhealthy diet, physical inactivity, carcinogenic infections, and air pollution are some of the risk factors for cancer. For instance, in the year 2018, about 13% of cancer diagnosed were attributed to carcinogenic infections such as Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus, as per the WHO, 2022.

Furthermore, technical innovation in the development of a variety of cancer diagnostic products would also contribute to the market in the forthcoming years. Integration of Artificial Intelligence (AI) technology in cancer care to improve the accuracy, speed and efficiency of cancer detection will also boost the cancer diagnostic market. For instance, in November 2022, FDA granted 510(k) clearance for Lunit AI solution to detect breast cancer.

Hence, all the aforementioned factors are projected to bolster the cancer diagnostic market during the forecasted period.

However, side effects associated with cancer imaging devices and the high cost of cancer diagnostic products are likely to impede the global cancer diagnostic market.

Additionally, the unprecedented COVID-19 pandemic had a negative impact on the cancer diagnostic market. This is due to the implementation of stringent regulations by most nations worldwide to curb infection transfer. Moreover, owing to the shift in focus on preserving health system capacity and also protecting high-risk patients from exposure to the virus, cancer patients have faced increased challenges in accessing care. For instance, as per the data provided by the National Cancer Institute 2022, besides the challenges associated with the lockdown restrictions due to the COVID-19 pandemic, it was observed that in March 2020 alone, COVID-19 forced the postponement of more than 800 appointments for lung cancer screening.

Cancer Diagnostic Market Segment Analysis:

Cancer Diagnostic Market By Type (Product Type [Reagent & Kits And Instruments], And Services), By Technique (Molecular Diagnostic [Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry], Diagnostic Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans], Endoscopy, Biopsy [Standard Biopsy and Liquid Biopsy]), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Cancer Diagnostic product type segment, the reagents & kits type held a significant market share of 66% which is expected to continue during the forecasted period. This is owing to the wide availability of reagents & kits for detecting cell signalling, cell proliferation and viability, tumor suppressor gene, bioactive proteins, and others in cancer cells.

Furthermore, approval of novel reagents and kits, which aid in early detection and proper management of various cancer types, by the regulatory bodies is also expected to boost the market growth for this segment.

For instance, on August 05, 2022, Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, received the Premarket Approval (PMA) for its oncoReveal(TM) Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.

Also, rising research and development activities by the key manufacturers are another factor projected to contribute to the segmental growth of the cancer diagnostic market. For instance, in the year 2020, BD started a clinical trial to verify the clinical effectiveness of the HPV Nucleic Acid Genotyping Assay Kit for cervical cancer.

Thus, all the above-mentioned factors are expected to propel the cancer diagnostic market in the upcoming years.

North America is expected to dominate the overall Cancer Diagnostic Market:

Among all the regions, North America has occupied a major share of 42% in the overall Cancer Diagnostic market in 2020 and will continue to dominate during the forecasted period. This domination is due to significant factors such as the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management, among others.

For instance, as per the GLOBOCAN 2020 data, approximately, 2,281,658 people were diagnosed with cancer in the US in 2020.

Furthermore, the rise in smoking among adults in the country could be a potential factor for lung cancer development which would, in turn, increase the cancer diagnostic market.

For instance, as per the CDC 2020 data, an estimated 34.1 million adults in the United States smoked cigarettes in 2019.

Moreover, approval of products to enhance the imaging technology for various cancer detection would also contribute to the market. Recently, on November 29, 2022, FDA approved Cytalux (pafolacianine), a targeted fluorescent imaging agent intended to assist surgeons in identifying ovarian cancer lesions.

Hence, the interplay of all the above-mentioned factors will augment the cancer diagnostic market in the country during the forecasted period.

Further, the Asia Pacific region has the future potential for the Cancer Diagnostic market. This is predominantly due to the burgeoning cases of cancer, rising risk factors among the population that potentially lead to the development of cancer, growing government initiatives regarding cancer care and its detection, among others. For instance, New Zealand launched Cancer Action Plan 2019-2029, the plans enable the Cancer Control Agency, the Ministry of Health, the sector, and all those affected by cancer to work collaboratively to prevent cancer and improve detection, diagnosis, treatment, and care after treatment. Thus, all the factors stated above will make APAC the fastest growing cancer diagnostic market in the forthcoming years.

Cancer Diagnostic Market Key Players:

Some of the key market players operating in the Cancer Diagnostic market include Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, and others.

Recent Developmental Activities in the Cancer Diagnostic Market:

In November 2022, Hologic, Inc. commercially launched its new Genius(TM) Digital Diagnostics System in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women.

In June 2022, NeoGenomics completed its acquisition for Inivata Ltd, a global, commercial-stage liquid biopsy platform company headquartered in Cambridge, England.

In August 2020, HTG Molecular Diagnostics, Inc. signed a commercialization and distribution agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly-owned subsidiary of QIAGEN N.V. for companion diagnostic (CDx) assays based on HTG EdgeSeq, HTG's novel RNA platform.

Key Takeaways from the Cancer Diagnostic Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Cancer Diagnostic market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Cancer Diagnostic Market.

Various opportunities available for the other competitor in the Cancer Diagnostic Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Cancer Diagnostic market growth in the coming future?

Target Audience who can be benefited from the Cancer Diagnostic Market Report Study

Cancer Diagnostic providers

Research organizations and consulting companies

Cancer Diagnostic-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Cancer Diagnostic

Various End-users who want to know more about the Cancer Diagnostic Market and the latest technological developments in the Cancer Diagnostic market.

Frequently Asked Questions for the Cancer Diagnostic Market:

1. What is Cancer Diagnostic?

Cancer Diagnostic is a necessary step towards the proper management of cancer and its progression. There is no single test that can accurately diagnose cancer; the complete evaluation usually requires a thorough history and physical examination along with diagnostics testing. Effective diagnostic testing is used to confirm or eliminate the presence of disease, monitor the disease process, and plan for and evaluate the effectiveness of treatment. Diagnostic procedures for cancer may include lab tests, tumor biopsy, endoscopic examination, and imaging.

2. What is the market for Global Cancer Diagnostic?

The global cancer diagnostic market was valued at USD 125.13 billion in 2023, growing at a CAGR of 9.43% during the forecast period from 2024 to 2030, to reach USD 214.88 billion by 2030.

3. What are the drivers for the Global Cancer Diagnostic?

The major factors driving the demand for Cancer Diagnostic are the rising cases of cancer across the globe. Moreover, technological innovation in cancer diagnostic products, increase in product launches, and rise in business expansion activities among key players, and others are expected to propel the cancer diagnostic market.

4. What are the key players operating in Global Cancer Diagnostic?

5. Which region has the highest share in the Cancer Diagnostic market?

1.Cancer Diagnostic Market Report Introduction

2. Cancer Diagnostic Market Executive summary

2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking

3. Regulatory Analysis

3.1 The United States
3.2 Europe
3.3 Japan
3.4 China

4. Cancer Diagnostic Market Key factors analysis

4.1 Cancer Diagnostic Market Drivers
- 4.1.1 Growing Incidence of Cancer across the Globe
- 4.1.2 Technical Innovation in Product Development
- 4.1.3 Growing Strategic Business Activities among Cancer Diagnostic Product Manufacturers
- 4.1.4 Rising Launch of Cancer Diagnostic Products
4.2 Cancer Diagnostic Market Restraints and Challenges
- 4.2.1 Side Effects Associated with the Cancer Imaging Devices
- 4.2.2 High Cost of Cancer Diagnostic Product and Limited Efficiency of Some Products
4.3 Cancer Diagnostic Market Opportunities
- 4.3.1 Increasing Awareness about Cancer Diagnostic
- 4.3.2 Increasing Healthcare Expenditure in Developing Countries

5. Cancer Diagnostic Porter's Five Forces Analysis

5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Cancer Diagnostic Market

7. Cancer Diagnostic Market layout

7.1 By Type
- 7.1.1 Product Type
  - 7.1.1.1 Reagents & Kits
  - 7.1.1.2 Instruments
- 7.1.2 Services
7.2 By Technique
- 7.2.1 Molecular Diagnostic
  - 7.2.1.1 Polymerase Chain Reaction
  - 7.2.1.2 Next Generation Sequencing
  - 7.2.1.3 Fluorescent In-Situ Hybridization
  - 7.2.1.4 Microarray
  - 7.2.1.5 Immunohistochemistry
- 7.2.2 Diagnostic Imaging
  - 7.2.2.1 Ultrasound & Radiology
  - 7.2.2.2 Mammography
  - 7.2.2.3 MRI Scan
  - 7.2.2.4 CT Scan
  - 7.2.2.5 Nuclear Medicine Scans
- 7.2.3 Endoscopy
- 7.2.4 Biopsy
  - 7.2.4.1 Standard Biopsy
  - 7.2.4.2 Liquid Biopsy
7.3 By Cancer Type
- 7.3.1 Breast Cancer
- 7.3.2 Colorectal Cancer
- 7.3.3 Lung Cancer
- 7.3.4 Prostate Cancer
- 7.3.5 Others
7.4 By End-user
- 7.4.1 Hospitals
- 7.4.2 Diagnostic Laboratories
- 7.4.3 Diagnostic Imaging Centers
- 7.4.4 Others
7.5 By Geography
- 7.5.1 North America
  - 7.5.1.1 United States
  - 7.5.1.2 Canada
  - 7.5.1.3 Mexico
- 7.5.2 Europe
  - 7.5.2.1 France
  - 7.5.2.2 Germany
  - 7.5.2.3 United Kingdom
  - 7.5.2.4 Italy
  - 7.5.2.5 Spain
  - 7.5.2.6 Russia
  - 7.5.2.7 Rest of Europe
- 7.5.3 Asia-Pacific
  - 7.5.3.1 China
  - 7.5.3.2 Japan
  - 7.5.3.3 India
  - 7.5.3.4 Australia
  - 7.5.3.5 South Korea
  - 7.5.3.6 Rest of Asia Pacific
- 7.5.4 Rest of the World (RoW)
  - 7.5.4.1 Middle East
  - 7.5.4.2 Africa
  - 7.5.4.3 South America

8. Cancer Diagnostic Global Company Share Analysis - Key 3-5 Companies

9. Cancer Diagnostic Company and Product Profiles

9.1 Pillar Biosciences, Inc.
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4 Product Listing
- 9.1.5. Entropy
9.2 Hologic Inc.
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4 Product Listing
- 9.2.5. Entropy
9.3 CD Genomics
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4 Product Listing
- 9.3.5. Entropy
9.4 Natera, Inc.
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4 Product Listing
- 9.4.5. Entropy
9.5 Agendia Inc.
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4 Product Listing
- 9.5.5. Entropy
9.6 Biodesix Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4 Product Listing
- 9.6.5. Entropy
9.7 INOVIQ Ltd.
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4 Product Listing
- 9.7.5. Entropy
9.8 HTG Molecular Diagnostics Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4 Product Listing
- 9.8.5. Entropy
9.9 Bio-Rad Laboratories, Inc.
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4 Product Listing
- 9.9.5. Entropy
9.10 Koninklijke Philips N.V.
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4 Product Listing
- 9.10.5. Entropy
9.11 FUJIFILM Holdings Corporation
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4 Product Listing
- 9.11.5. Entropy
9.12 Abbott
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4 Product Listing
- 9.12.5. Entropy
9.13 General Electric Company
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4 Product Listing
- 9.13.5. Entropy
9.14 Thermo Fisher Scientific Inc.
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4 Product Listing
- 9.14.5. Entropy
9.15 NeoGenomics Laboratories
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4 Product Listing
- 9.15.5. Entropy
9.16 F. Hoffmann-La Roche Ltd
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4 Product Listing
- 9.16.5. Entropy
9.17 Agilent Technologies Inc
- 9.17.1. Company Overview
- 9.17.2. Company Snapshot
- 9.17.3. Financial Overview
- 9.17.4 Product Listing
- 9.17.5. Entropy
9.18 Guardant Health
- 9.18.1. Company Overview
- 9.18.2. Company Snapshot
- 9.18.3. Financial Overview
- 9.18.4 Product Listing
- 9.18.5. Entropy
9.19 Illumina, Inc.
- 9.19.1. Company Overview
- 9.19.2. Company Snapshot
- 9.19.3. Financial Overview
- 9.19.4 Product Listing
- 9.19.5. Entropy
9.20 QIAGEN
- 9.20.1. Company Overview
- 9.20.2. Company Snapshot
- 9.20.3. Financial Overview
- 9.20.4 Product Listing
- 9.20.5. Entropy